Merck Enters into a Development Agreement with Daiichi for Antibody Drug Conjugates

On 23 October 2023, Merck announced a development agreement for Daiichi Sankyo’s clinical-phase antibody-drug conjugate, namely patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd), targeting cancer. Merck has invested $5.5 billion to jointly develop three of its candidate cancer drugs and is likely to invest up to $22 billion in addition depending on the success of the cell-targeting therapies.

Patritumab deruxtecan is being evaluated for the treatment of EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) with disease progression on or after treatment with a third-generation tyrosine kinase inhibitor (TKI) and platinum-based therapies. Ifinatamab deruxtecan is under study as a monotherapy in Phase II in patients previously treated extensive-stage small cell lung cancer. Raludotatug deruxtecan (R-DXd) is being assessed in a first-in-human Phase I trial for patients with advanced ovarian cancer.

The three ADCs are designed to target and deliver a cytotoxic payload inside cancer cells that express a specific cell surface antigen, using Daiichi Sankyo’s DXd ADC technology. Each ADC consists of a monoclonal antibody attached to a number of topoisomerases I inhibitor payloads via tetrapeptide-based cleavable linkers.

According to Roots Analysis, the antibody drug conjugate market is estimated to be worth $7.72 billion in 2023 and is expected to grow at CAGR of 9.63% during the forecast period.

For detailed insights about this domain, check out our report on Antibody Drug Conjugate Market or email

You may also be interested in the following titles: